



Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609
07/19/2021

Sent via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: New Drug Introduction Notification pursuant to 18 V.S.A. § 4637(c) and (d)

To the Office of the Attorney General of Vermont.

On 06/21/2021, and pursuant to 18 V.S.A. § 4637(b), Puma Biotechnology, Inc. ("Puma") provided to the State of Vermont new drug notices for Nerlynx (**NDC 70437-0240-33**).

Pursuant to 18 V.S.A. § 4637(c), and pertaining to Nerlynx (**NDC 70437-0240-33**), Puma submits the following additional information:

1. US and International marketing and pricing plans used at launch:

Because this information is not in the public domain or publicly available and is confidential, Puma declines to provide this information in accordance with 18 V.S.A. §4637(d).

2. Estimated volume of patients who may be prescribed the drug:

The estimated number of patients that will be prescribed Nerlynx is 3350.

3. Whether the FDA granted breakthrough therapy designation or priority review:

Nerlynx has not received priority review or breakthrough status.

4. Date and price of acquisition:

N/A. Puma did not acquire Nerlynx.

If you have any further questions, please do not hesitate to contact me.

Regards,

Michael Flinn

Director, Contracting Trade and Distribution

Puma Biotechnology, Inc.
701 Gateway Blvd., 5th Floor
South San Francisco, CA 94080
Mobile (650) 515-2160
Office (424)248-6500 ext 3093

10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024

424.248.6500